Adamas Pharma (ADMS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2021 | 06-2021 | 03-2021 | 12-2020 | 09-2020 | |
| Sales | 25,896 | 21,972 | 19,311 | 21,010 | 20,176 |
| Cost of Goods | 576 | 527 | 385 | 597 | 488 |
| Gross Profit | 25,320 | 21,445 | 18,926 | 20,413 | 19,688 |
| Operating Expenses | 31,532 | 31,127 | 28,836 | 35,987 | 28,941 |
| Operating Income | -5,636 | -9,155 | -9,525 | -14,977 | -8,765 |
| Interest Expense | 3,497 | 3,469 | 3,432 | 3,390 | 3,506 |
| Other Income | -10,385 | 280 | 384 | 94 | 355 |
| Pre-tax Income | -19,518 | -12,344 | -12,573 | -18,273 | -11,916 |
| Net Income Continuous | -19,518 | -12,344 | -12,573 | -18,273 | -11,916 |
| Net Income | $-19,518 | $-12,344 | $-12,573 | $-18,273 | $-11,916 |
| EPS Basic Total Ops | -0.43 | -0.27 | -0.36 | -0.65 | -0.42 |
| EPS Basic Continuous Ops | -0.43 | -0.27 | -0.36 | -0.64 | -0.42 |
| EPS Diluted Total Ops | -0.43 | -0.27 | -0.36 | -0.65 | -0.42 |
| EPS Diluted Continuous Ops | -0.43 | -0.27 | -0.36 | -0.64 | -0.42 |
| EPS Diluted Before Non-Recurring Items | -0.43 | -0.27 | -0.36 | -0.64 | -0.42 |
| EBITDA(a) | $-5,486 | $-9,039 | $-9,455 | $-14,769 | $-8,570 |